RxDoctor Payments Data

Cary Bortnick, MD

Internal Medicine · Delray Beach, FLNPI 1407941255

Payments from drug & device makers

$2,688in general payments, 2019–2025

Across 162 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$556
  • GSK$416
  • AstraZeneca$281
  • Pfizer$245
  • Novartis$195
  • Lilly USA, LLC$137
  • plus $858 from 22 others

What the payments were for

  • Food & beverage$2,676100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,688 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$22,147
Medicare patients
86
Services billed
238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide26$30,775
OzempicSemaglutide16$15,186
MyrbetriqMirabegron14$11,767
Atorvastatin Calcium123$1,166
Tamsulosin Hcl36$669
Losartan Potassium83$560
Amlodipine Besylate99$425
Rosuvastatin Calcium52$331
Nifedipine ErNifedipine13$292
Famotidine20$289
Levothyroxine Sodium33$243
Lisinopril44$234
Montelukast Sodium15$220
Metformin Hcl27$216
Gabapentin20$203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$137$30,77526 claims
Novo NordiskOzempic$56$15,18616 claims
Astellas Pharma US IncMyrbetriq$12$11,76714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Delray Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →